Bullish indicating open at $55-$60, IPO prices at $37
Cellebrite DI stock reached a 52-week low, hitting a price of 13.15 USD. According to InvestingPro data, technical indicators suggest the stock is oversold, with impressive gross profit margins of 84%. This milestone marks a significant point for the company, as the stock’s performance over the past year reflects a modest increase of 1.72%. The dip to this new low comes amid a fluctuating market environment, where investors are closely monitoring the company’s strategic moves and financial health. With revenue growing at 22% and a healthy current ratio of 1.82, the company maintains strong fundamentals. Despite the recent downturn, the slight annual gain indicates some resilience in the stock’s long-term trajectory. As Cellebrite DI continues to navigate the complexities of the tech sector, stakeholders will be keen to see how the company positions itself for future growth, with analysts setting price targets between $20-$28. Get deeper insights and 12 additional ProTips with InvestingPro.
In other recent news, Cellebrite has announced a significant agreement to acquire Corellium for $170 million in cash, with an additional $30 million contingent on performance milestones. This acquisition is expected to close in the summer of 2025, subject to regulatory approvals, and aims to bolster Cellebrite’s capabilities in digital investigations and smart device security. Additionally, the U.S. Department of Justice will sponsor Cellebrite in its pursuit of FedRAMP High authorization for its government cloud platform, a crucial step towards achieving full Authorization to Operate status. In a leadership change, Cellebrite has appointed David Barter as its new Chief Financial Officer, following the retirement of Dana Gerner, who will remain in an advisory capacity until the second quarter of 2025. These developments mark a period of strategic growth and leadership transition for Cellebrite.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.